Global Cancer Cachexia Market Share, Research Report, Analysis 2024-2032

IMARC Group, a leading market research company, has recently releases report titled "Cancer Cachexia Market Report by Therapeutics (Progestogens, Corticosteroids, Combination Therapy, and Others), Mode of Action (Appetite Stimulators, Weight Loss Stabilizers), Distribution Channel (Hospital Stores, Retail Pharmacy, Online Pharmacy), and Region 2024-2032", Offers a comprehensive analysis of the industry, which comprises insights on the global cancer cachexia market.

How Big Is the Cancer Cachexia Market?

The global cancer cachexia market size reached US$ 2.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 3.0 Billion by 2032, exhibiting a growth rate (CAGR) of 4.1% during 2024-2032.

Industry Overview of Cancer Cachexia

Cancer cachexia refers to a waste syndrome characterized by systematic inflammation, negative protein balance, loss of lean body mass, diminished appetite, and muscle atrophy. It is a multifactorial, host-phagocytic condition caused by chronic diseases like tuberculosis (TB), chronic obstructive pulmonary disease (COPD), multiple sclerosis, and human immunodeficiency virus (HIV). To address cancer cachexia, therapeutic options like progestogen, corticosteroid, and combination therapy can be employed. Progestogen, a synthetic or natural steroid hormone, enhances appetite and promotes weight gain, while corticosteroid helps alleviate inflammation and suppresses hyperactive immune systems.

For an in-depth analysis, you can refer sample copy of the report: https://www.imarcgroup.com/cancer-cachexia-market/requestsample

What are the growth prospects and trends in the cancer cachexia industry?

The increasing occurrence of cancer cachexia, particularly among the expanding elderly populations, and the inflating need for advanced therapeutic remedies and medications are primarily augmenting the market’s growth. Additionally, the elevating awareness among consumers regarding the accessibility of innovative therapeutic medications to address cancer cachexia is further propelling the market growth.

Besides this, the growing preference of patients towards combined therapies to enhance lean body mass (LBM) through pharmacological and non-pharmacological interventions and clinical trials is acting as another significant growth-inducing factor. Furthermore, the rising utilization of various appetite stimulants, including megestrol acetate, dexamethasone, and methylprednisolone, to improve digestion is also contributing to market growth.

Apart from this, the continuous technological advancements emphasizing the development of effective medications for treating cancer cachexia are offering lucrative growth opportunities to the market. Additionally, the positive market outlook is being created by various favorable initiatives undertaken by government entities and non-governmental organizations (NGOs) in different countries to raise awareness about the causes of cancer cachexia, its symptoms, and the benefits of advanced treatments.

Leading Companies Operating in the Global Cancer Cachexia Industry:

• AAVogen Inc.
• Actimed Therapeutics Ltd.
• Aphios Corporation
• Artelo Biosciences Inc.
• AVEO Pharmaceuticals Inc.
• Fresenius Kabi AG (Fresenius SE & Co. KGaA)
• Helsinn Healthcare SA
• Merck & Co. Inc.
• NGM Biopharmaceuticals Inc.
• Pfizer Inc.
• Tetra Bio-Pharma

Cancer Cachexia Market Report Segmentation:

The report has segmented the market into the following categories:

Breakup by Therapeutics:

• Progestogens
• Corticosteroids
• Combination Therapy
• Others

Breakup by Mode of Action:

• Appetite Stimulators
• Weight Loss Stabilizers

Breakup by Distribution Channel:

• Hospital Stores
• Retail Pharmacy
• Online Pharmacy

Breakup by Region:

• North America: (United States, Canada)
• Asia Pacific: (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe: (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America: (Brazil, Mexico, Others)
• Middle East and Africa

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC Group’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163

Imarc Group is a leading market research and consulting company that offers management strategy and market research worldwide.